Joanne Blum, MD, PhD, oncologist with Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discuses the EMBRACA trial.
Joanne Blum, MD, PhD, oncologist, Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discusses the EMBRACA trial.
The trial is a phase III, open-label, randomized, parallel, two-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in patients with BRCA-mutated metastatic breast cancer. The trial aims to include about 429 patients, says Blum, but it is event-driven so it is possible there might be fewer.
The patients included in this trial are rare, says Blum. Patients with a BRCA mutation amount to approximately 7% of the general breast cancer population and only a few of them develop metastatic disease. To identify enough patients for this trial takes a worldwide effort, says Blum. There are plans to expand it even further to more countries and sites in the near future.